Quick Answer
Corvus Pharmaceuticals, Inc. reported Net Income Loss of -$15.28 million for the year ending 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +75.5% in Net Income Loss from 2024 to 2025.
- This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Corvus Pharmaceuticals, Inc.'s Net Income Loss has declined by 9,392.5%.
- Historical annual values: Fiscal year 2025: -$15.28 million | Fiscal year 2024: -$62.29 million | Fiscal year 2023: -$27.03 million | Fiscal year 2022: -$41.31 million | Fiscal year 2021: -$43.24 million | Fiscal year 2020: -$6.00 million | Fiscal year 2019: -$46.67 million | Fiscal year 2018: -$46.94 million | Fiscal year 2017: -$55.66 million | Fiscal year 2016: -$36.38 million | Fiscal year 2015: -$31.34 million | Fiscal year 2014: -$161.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: